ABOUT THE BIOTECH CEO SUMMITS – UNLIKE ANY OTHER CONFERENCE
The Biotech CEO Summits are unlike most other meetings CEOs attend. The Summits focus on the participating CEOs discussing issues of importance to them as leaders of companies they want to position for growth and success. The Summits are discussion based meetings led by subject matter experts. All participants are invited to, and indeed encouraged to join the discussions by asking questions and sharing their personal insights. The Summits are run under Chatham House Rules to encourage open and frank conversation. The media are not invited, and the sessions are not recorded, to provide an extra layer of privacy.
2024 Agenda
Monday, May 27
| 14:00 |
Registration: Main Lobby |
| 16:30 |
Icebreaker Activity/Networking Reception: Dolce Vita Patio Meet your fellow CEOs |
| 18:45 |
Welcome & Opening Remarks: Dolce Vita Garden Sara Jane Demy, Founder & CEO, Demy-Colton |
| 19:00 |
CEO Summit Participant Introductions: Dolce Vita Garden |
| 19:30 |
Fireside Chat Series: The Purposeful CEO – Fulfilling the Promise: Dolce Vita Garden Biotech CEOs are committed to improving the health of patients. The path they take to fulfill their objective of delivering better health outcomes is challenging and requires risk-taking on many levels.
|
| 20:15 |
Networking Reception & Dinner: Terraza de la Taula |
Tuesday, May 28
| 07:30 |
Private Networking Breakfast: Entre Venias Patio |
| 08:30 |
Summit Overview & Rules of Engagement: Ra Conference Room |
| 08:45 |
The Bioeconomy: Where Are We Today and Where Will We Be as We Head into 2025 With a change in the tides after a previously fractured economy, will the biotech sector in Europe keep its rightful place as a leader in innovation? Let’s discuss the predictions from our experts and consider how this will affect your company’s journey.
|
|
09:30 |
Fundraising: Patience, Persistence, and Performance Pays in All Market Conditions A discussion about building relationships with the investing community and potential partners that will lead to an investment or partnership to support your company. We will also discuss how building confidence in your company will make others view it positively.
|
| 10:15 |
Networking Break: Bamboo Garden |
|
10:30 |
The Path(s) Forward: Understanding the Strategic Options Are you planning to go it alone, be acquired, or partner select assets? Let’s discuss various options to help advance your company.
|
| 11:15 |
For Successful BD and Fundraising: Every Company Has to Understand How Any Asset Will be Commercialized, Even at an Early Stage It is critical for any company to demonstrate that they have a thorough understanding of how they will commercialize their assets, even at an early stage. Let’s explore strategies for successful product commercialization.
|
| 12:00 |
The Evolving Regulatory Environment: Changes Underway in Europe and the US and How it Will Affect Market Access The proposed European Parliament legislative overhaul designed to make Europe more attractive for the biopharma industry may not be so attractive. And, on the US side, is the IRA a Pandora’s box?
|
| 13:00 |
Networking Lunch: D.O. Terraza |
| 14:30 |
Commercialization (and Licensing): Which Markets are Right for Your Product and Company? Often, EU companies that are planning for commercialization will target the US market because of its size and the fact that it is a single market while not targeting local markets or other regional markets. Let’s discuss the options, resources, and tactics for both.
|
| 15:15 |
Valuation Case Study Overview
|
| 15:35 |
Valuation Case Study Breakout: Art Rooms
|
| 16:10 |
Valuation Report Back: Ra Conference Room
|
| 16:30 |
Boards: The Inherent Challenges of a Biotech Board
|
| 17:15 |
Day 1 Wrap-Up & Instructions for Games Sara Jane Demy, Founder & CEO, Demy-Colton Sara Pinto, Managing Director, Program Development, Demy-Colton |
| 17:30 |
Break |
| 18:00 |
Biotech CEO Summit Europe Games: Entre Venias Patio |
| 19:30 |
Break before Dinner |
| 20:00 |
Biotech CEO Summit Europe Gala Dinner: Pool Deck
|
Wednesday, May 29
| 07:30 |
Private Networking Breakfast: Entre Venias Patio |
| 08:45 |
Welcome Back & Day 2 Commences: Ra Conference Room Sara Jane Demy, Founder & CEO, Demy-Colton |
| 09:00 |
Communication: A Tool to Achieve Your Corporate Goals Communication is critical for biotech companies because potential investors, partners and, ultimately, payers, doctors and patients will make their decisions based on two things: their awareness of the benefit of your product(s); and trust. We will explore the role of communication and its impact on achieving corporate goals, with a focus on external and internal alignment and cultural differences.
|
| 09:45 |
Your Board: Shaping them Into Your Most Important Asset Continuing yesterday’s conversation and learning from each other.
|
| 10:30 | Networking Break: Bamboo Garden |
| 11:00 |
Building a Smart Team & Keeping Them: The Essentials for Success The team surrounding a CEO is critical to the success of the company. How do you assess the strengths of your team to understand its weaknesses to identify your needs?
|
| 11:45 |
Being a CEO Who Leads Through Difficult Times A conversation with CEOs who have made it to the other side of countless challenges. What does it take personally and professionally to persevere and prosper in changing times.
|
| 12:30 |
An Unguarded Conversation Among Friends Is being a biotech CEO really the loneliest job in the world? |
| 13:15 |
Wrap Up Biotech CEO Summit Sara Jane Demy, Founder & CEO, Demy-Colton |
| 13:30 |
Networking Luncheon and Closing: D.O. Terraza |
List of 2024 Discussants:
Renée Aguiar-Lucander, CEO, Calliditas Therapeutics AB
Paula Burke, Director, Life Sciences & Healthcare, HSBC Innovation Banking
Peter Feinstein, Co-Founder, BioVentures Investors
Patrik Frei, Founder & CEO, Venture Valuation AG
Juan Garcia, Managing Director, Biotechnology Business Institute
Eddie Gibson, Founder, Wickenstones Ltd
Ted Haack, Vice President, LatticePoint
Stephanie Léouzon, Managing Director & Vice Chair of European Healthcare, Stifel
Chris Maggos, Managing Director, Cohesion Bureau
Jeffrey Meckler, CEO, Indaptus Therapeutics, Inc.
Jeff Myers, Senior Vice President, Reimbursement Strategy and Market Access, Catalyst Healthcare Consulting (via Zoom)
Pankaj Oza, Managing Partner, Blue Matter
Joris Pezzini, EVP Biopharma, Alira Health
Penny Sadler, Client Partner, Coulter Partners
Gretchen Schweitzer, Managing Director, Trophic Communications
Denise Scots-Knight, CEO, Mereo BioPharma Group
Thomas Tóth von Kiskér, CEO, Tillotts Pharma AG
Claudia Ulbrich, CEO, Cardior Pharmaceuticals
Wills Hughes Wilson, Chief Patient Access & Commercial Planning, Mereo BioPharma